Statement of Changes in Beneficial Ownership (4)
2016年7月27日 - 6:27AM
Edgar (US Regulatory)
|
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
FRIEDMAN PAUL A
|
2. Issuer Name
and
Ticker or Trading Symbol
SYNTA PHARMACEUTICALS CORP
[
MDGL
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Executive Officer
|
|
(Last)
(First)
(Middle)
C/O MADRIGAL PHARMACEUTICALS, INC., 500 OFFICE CENTER DRIVE, SUITE 400
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/22/2016
|
|
(Street)
FORT WASHINGTON, PA 19034
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Common Stock
|
7/22/2016
|
|
A
|
|
146
(1)
|
A
|
$0
|
146
|
D
|
|
|
Common Stock
|
7/22/2016
|
|
A
|
|
143557
|
A
|
$0
|
143703
|
D
|
|
|
Common Stock
|
7/22/2016
|
|
A
|
|
729066
(2)
|
A
|
$0
|
729066
|
I
|
SQN, LLC
(3)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Employee Stock Option (Right to Buy)
|
$9.45
|
7/22/2016
|
|
A
|
|
287115
|
|
7/22/2016
|
7/22/2026
|
Common Stock
|
287115
|
$0
|
287115
|
D
|
|
|
Explanation of Responses:
|
|
(
1)
|
On July 22, 2016, the common stock of Madrigal Pharmaceuticals, Inc. (f/k/a Synta Pharmaceuticals Corp.) underwent a 1-to-35 reverse split, resulting in Dr. Friedman's owning 146 shares of common stock.
|
|
(
2)
|
Shares issued relate to the exchange of Madrigal Pharmaceuticals, Inc.,(as a private company), shares for Synta Pharmaceuticals Corp. per Synta's agreement to acquire Madrigal, dated April 13, 2016. After completion of the Merger, Synta Pharmaceuticals Corp. changed its name to Madrigal Pharmaceuticals, Inc.
|
|
(
3)
|
Dr. Friedman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
|
Remarks:
Exhibit List: Exhibit 24.1 Power of Attorney
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
FRIEDMAN PAUL A
C/O MADRIGAL PHARMACEUTICALS, INC.
500 OFFICE CENTER DRIVE, SUITE 400
FORT WASHINGTON, PA 19034
|
X
|
|
Chief Executive Officer
|
|
Signatures
|
|
/s/ Michael Lawhead, attorney-in-fact for Paul A. Friedman
|
|
7/26/2016
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 10 2024 まで 11 2024
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 11 2023 まで 11 2024
Real-Time news about Synta Pharmaceuticals Corp. (MM) (ナスダック市場): 0 recent articles
その他のSynta Pharmaceuticals Corpニュース記事
